BPC-157: A Pentadecapeptide for Gastrointestinal and Soft-Tissue Repair Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to BPC-157. BPC-157 is not FDA-approved for any indication and, as of September 2023, is classified as an FDA 503A Category 2 bulk drug substance, meaning it is prohibited for use in compounding by licensed pharmacies. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Athletes and wellness-oriented adults have been discussing BPC-157 online for years, and the volume of that conversation has grown faster than the clinical evidence behind it. Most of what is cited in those discussions comes from animal studies conducted predominantly by a single research group. The human data is sparse, methodologically limited, and nowhere near sufficient to support the claims commonly made about this compound.

Here is what BPC-157 actually is, what the research shows, what the FDA did about it in 2023, and what any serious reader should understand before forming an opinion about it.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication. As of September 2023, BPC-157 is classified as an FDA 503A Category 2 bulk drug substance — prohibited for use in compounding by licensed pharmacies in the United States.
• Research Stage: Primarily preclinical (animal models). Phase 1 human trials are described as underway by the originating research group, but no completed human efficacy trials have been published as of April 2026.
• Availability: BPC-157 cannot be legally obtained through a licensed compounding pharmacy in the United States. Superpower Health does not prescribe, sell, or facilitate access to BPC-157.
• Prescribing information: View compound reference data (PubChem CID 108101)
• How it works (proposed): Preclinical evidence suggests BPC-157 activates the VEGFR2-Akt-eNOS signaling pathway, modulates nitric oxide production, and engages the FAK-paxillin pathway in tendon fibroblasts — mechanisms studied in animal models.
• What the research shows: A 2025 systematic review by Vasireddi, Hahamyan, Salata, and colleagues in HSS Journal synthesized 36 studies (35 preclinical animal studies and 1 uncontrolled human chart review) published between 1993 and June 2024 and documented zero completed controlled human efficacy trials, a plasma half-life under 30 minutes, and no human clinical safety data.

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence of a protein found in human gastric juice. It was first characterized in the early 1990s by Sikirić, Seiwerth, and colleagues in two foundational papers: a 1994 report in Life Sciences by Sikirić, Seiwerth, Grabarević, Petek, Rucman, and colleagues comparing BPC 157 to H2 antagonists, dopamine agonists, and other gut peptides across restraint-stress, cysteamine, and 96% ethanol rat ulcer models, in which BPC 157 regimens were consistently effective across all three lesion models, and a 1993 Journal of Physiology (Paris) paper by Sikirić, Petek, Rucman, Seiwerth, and colleagues identifying the 15-amino-acid fragment (from a larger ~40,000 molecular-weight gastric juice protein) as the portion essential for the compound's activity. The compound is also known by its clinical program designation PL 14736, as well as bepecin, PLD-116, and PL-10 in various research and regulatory contexts.

BPC-157 is not a naturally occurring bioactive peptide in the conventional sense. It is a synthetic fragment — a laboratory-derived sequence derived from a larger gastric juice protein, with no naturally occurring isolated form that circulates in human biology at measurable concentrations. This distinction matters when evaluating claims about its mechanisms and effects.

Proposed Mechanisms: What the Preclinical Research Suggests

Nitric oxide pathway modulation

The most frequently cited mechanistic pathway in BPC-157 research involves nitric oxide (NO) signaling. A 2014 review by Sikirić, Seiwerth, Rucman, and colleagues in Current Pharmaceutical Design synthesized the BPC-157/NO-system literature, framing the peptide as acting in parallel with nitric oxide synthase modulators (L-NAME and L-arginine) and as preserving NO homeostasis across gastric, vascular, and wound-healing injury models. A subsequent 2020 study by Hsieh, Lee, Chueh, and Chang in Scientific Reports used isolated rat aorta to show a concentration-dependent, endothelium-dependent vasodilatory effect that was abolished by L-NAME or hemoglobin, and reported that BPC 157 increased phosphorylation of Src, Caveolin-1, and eNOS — an effect eliminated by Src inhibition — formally implicating the Src–Caveolin-1–eNOS cascade as an upstream driver of the NO response. A 2014 companion review by Seiwerth, Brcic, Sikirić, and colleagues in Current Pharmaceutical Design on BPC 157 and blood vessels, alongside a 2022 synthesis by Sikirić, Skrtic, Gojkovic, and colleagues in World Journal of Gastroenterology, frame these vascular effects as central to the compound's proposed organoprotective activity. These findings are from preclinical experiments; whether the pathway functions equivalently in humans under physiological conditions has not been established.

VEGFR2 and angiogenesis

A 2017 study by Hsieh and colleagues published in the Journal of Molecular Medicine reported that BPC-157 was associated with upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and activation of the downstream Akt-eNOS pathway in animal models of ischemia and wound healing. Increased angiogenesis — the formation of new blood vessels — was observed in treated tissue relative to controls. A 2009 study by Brcic, Staresinic, Novinscak, Sikirić, and Seiwerth in the Journal of Physiology and Pharmacology documented VEGF up-regulation and enhanced angiogenesis in rat muscle and tendon injury models following BPC 157 administration (with no direct pro-angiogenic effect in cell-culture controls), and a 2015 study by Huang and colleagues in Drug Design, Development and Therapy reported enhanced alkali-burn wound healing in vivo with parallel increases in proliferation, migration, and angiogenesis in vitro. A 2025 synthesis by Sikirić and colleagues in Pharmaceuticals (Basel) positions BPC-157 as a modulator of angiogenesis working through the NO system. Angiogenesis is a plausible mechanism for facilitating tissue repair; the evidence supporting it in this context is preclinical.

FAK-paxillin pathway in tendon and connective tissue

A 2011 study by Chang, Tsai, Lin, and colleagues in the Journal of Applied Physiology examined BPC-157's effects on tendon healing using a Sprague-Dawley rat Achilles transection model paired with cultured tendon fibroblasts, and identified dose-dependent activation of the focal adhesion kinase (FAK) and paxillin signaling cascade. FAK-paxillin signaling is involved in cell migration and survival in fibroblasts. The study reported significantly accelerated tendon-explant outgrowth, dose-dependent increases in fibroblast migration (with no direct effect on proliferation), and improved cell survival under oxidative stress in treated animals. A 2014 companion study by Chang and colleagues published in Molecules further reported that BPC-157 enhanced growth hormone receptor expression in tendon fibroblasts in vitro — the only published citation supporting the growth hormone receptor hypothesis for this compound. Earlier animal work by the Sikirić group, including a 2003 Achilles transection study by Staresinic and colleagues in the Journal of Orthopaedic Research, a 2010 medial collateral ligament study by Cerovecki and colleagues, a 2006 Achilles-to-bone study by Krivic and colleagues, a 2006 transected-quadriceps study by Staresinic and colleagues in the Journal of Orthopaedic Research, and a 1999 rabbit segmental bone defect study by Sebecić and colleagues in Bone, populate the wider connective-tissue literature these papers are built on. An independent 2019 systematic review by Gwyer, Wragg, and Wilson in Cell and Tissue Research cataloged this musculoskeletal soft-tissue evidence from outside the Sikirić lab.

Gastrointestinal cytoprotection and the organoprotection hypothesis

The original research framing for BPC-157 centered on gastrointestinal cytoprotection. The early Sikirić papers described protective effects on gastric and duodenal mucosa in rats subjected to stress, ethanol, and cysteamine injury. A 2020 synthesis by Sikirić, Seiwerth, Rucman, and colleagues in Gut and Liver reviewed more than 25 years of this work and framed BPC 157 as a mediator of Robert's stomach cytoprotection / adaptive cytoprotection / organoprotection model and of Selye's stress-coping response — building on the broader cytoprotection concept introduced by Robert in the 1980s. The clinical program that followed this work, using the designation PL 14736, did reach Phase 2 trials in inflammatory bowel disease; a 2012 review by Sikirić and colleagues in Current Medicinal Chemistry covered this program, and a 2007 study by Vuković and colleagues in Surgery Today documented healing of ileoileal anastomosis in rats under the PL-14736 program designation. Those clinical trials were not completed with sufficient endpoints to support regulatory approval. Mechanistic work has also extended into the gut-brain axis, as summarized in a 2016 review by Sikirić and colleagues in Current Neuropharmacology, a 2019 study by Wang, Qu, Duan, and colleagues in Neuroscience Bulletin showing that BPC 157 increased survival of cultured enteric neurons and proliferation of enteric glial cells isolated from rat ileum and colon, and enhanced enteric 5-HT release, a 2022 central-nervous-system review by Vukojević, Sikirić, and colleagues in Neural Regeneration Research, a 2019 rat spinal cord injury study by Perovic and colleagues in the Journal of Orthopaedic Surgery and Research, and a 2010 transected-sciatic-nerve study by Gjurašin, Boban Blagaić, Sikirić, and colleagues in Regulatory Peptides reporting faster axonal regeneration, increased myelinated-fiber density, and improved nerve-fascicle presentation in BPC 157-treated rats. A 2021 wound-healing review by Seiwerth and colleagues in Frontiers in Pharmacology and a 2024 pleiotropic-activity review by Sikirić and colleagues in Pharmaceuticals (Basel) attempt to consolidate these cross-system findings into a single mechanistic framework — all of which remains preclinical.

What the Human Evidence Actually Shows

The evidence base is almost entirely preclinical

The 2025 systematic review by Vasireddi, Hahamyan, Salata, and colleagues, published in HSS Journal, examined the full published orthopaedic-sports-medicine literature on BPC-157 — 36 studies (35 preclinical, 1 clinical) from 1993 through June 2024. The review found no completed controlled human efficacy trials. The only published data with human subjects is a 2021 retrospective uncontrolled chart review by Lee and Padgett in Alternative Therapies in Health and Medicine (volume 27, issue 4), covering intra-articular knee injections in 16 patients (12 receiving BPC-157 alone, 4 receiving BPC-157 combined with TB-4) followed for 6 to 12 months. The authors reported that 11 of 12 BPC-157-only patients (91.6%) and 14 of 16 overall (87.5%) experienced subjective knee-pain relief based on phone-survey self-report; no standardized functional or quality-of-life instruments were used, no control group was included, no randomization was performed, and the study was conducted at a single private hormone-balance clinic. No adverse events were reported in the abstract. The absence of a comparator, the phone-survey outcome methodology, and the small single-center cohort together mean this is the entirety of published human efficacy data on BPC-157 as of April 2026 — and it cannot support generalizable conclusions. A 2025 literature and patent review by Józwiak and colleagues in Pharmaceuticals (Basel) confirmed this picture: no FDA approval, no completed efficacy trials in humans, and WADA prohibition status.

Literature concentration and independence concerns

A separate concern relevant to evaluating BPC-157 research is that the overwhelming majority of published studies originate from a single research group centered on Sikirić at the University of Zagreb. The 2025 Vasireddi review documented this concentration explicitly. Independent replication — studies from unaffiliated laboratories reproducing the key animal findings — is limited. The non-Sikirić citations that do exist include the Hsieh VEGFR2 work from 2017, the Chang FAK-paxillin tendon study from 2011 and its 2014 growth-hormone-receptor follow-up, an independent 2019 systematic review by Gwyer, Wragg, and Wilson in Cell and Tissue Research, and the 2019 Wang, Qu, Duan enteric neuron paper in Neuroscience Bulletin. Independent replication matters because single-laboratory findings in animal models have a well-documented tendency not to translate to human clinical outcomes.

Half-life and bioavailability constraints

The Vasireddi 2025 systematic review documented a plasma half-life for BPC-157 of under 30 minutes in animal pharmacokinetic studies, along with hepatic metabolism and renal clearance. Short half-life is relevant to mechanism evaluation because it constrains how long the compound could plausibly sustain the signaling effects proposed in longer-duration animal healing models. Bioavailability and pharmacokinetic data in humans are not published.

Regulatory and Legal Status

FDA 503A Category 2 classification

As of September 2023, BPC-157 is classified as a Category 2 bulk drug substance on the FDA's 503A bulk substances list — the category for substances that may present significant safety risks and are prohibited for use in compounding. The FDA's interim list of bulk drug substances for compounding reflects this classification. This means that licensed 503A compounding pharmacies in the United States cannot legally compound BPC-157. Any product marketed or sold as BPC-157 for human use in the United States falls outside the legal framework for regulated pharmaceutical compounding.

WADA prohibition

As of the 2022 WADA Prohibited List, BPC-157 is prohibited at all times under Section S0 (Unapproved Substances). The S0 category covers pharmacological substances not approved by any governmental regulatory health authority for human therapeutic use. BPC-157 is not eligible for a Therapeutic Use Exemption (TUE) under this classification. The U.S. Anti-Doping Agency has published specific guidance confirming this prohibition and noting that BPC-157 has been found in health and wellness products marketed outside pharmaceutical channels. Athletes subject to WADA testing who use or have used BPC-157 in any form face the risk of a positive test result.

What this means practically

BPC-157 cannot be obtained through a licensed compounding pharmacy in the United States. Products marketed as BPC-157 for human use exist in unregulated channels — research chemical vendors, peptide suppliers, and online marketplaces operating outside pharmaceutical oversight. These products have no quality control, no sterility guarantee, no verified purity, no established dosing data, and no regulatory accountability. The FDA Category 2 classification reflects the agency's assessment that the available evidence does not support safe use in compounding, and the WADA ban reflects that no regulatory body has approved it for human therapeutic use.

Safety: What Is and Is Not Known

Animal safety data for BPC-157 is generally reassuring within the scope of what has been studied. A 2020 preclinical GLP safety evaluation by Xu and colleagues published in Regulatory Toxicology and Pharmacology examined BPC-157 across mice (BALB/c and ICR), rats (Sprague-Dawley), rabbits, and dogs using repeated-dose, genotoxicity, local-irritation, and embryo-fetal protocols, and reported that the compound was well tolerated with no serious toxicity, no genotoxic signal, no embryo-fetal toxicity, and only mild local irritation; one high-dose decrease in canine creatinine was attributed to pharmacological activity rather than toxicity. These are formal preclinical GLP studies, which represent the best available safety data for any investigational compound — but they remain preclinical, and no equivalent human toxicology package has been published.

The critical limitation is that no equivalent human safety database exists. Preclinical toxicology findings frequently do not predict human adverse effects, and the absence of reported toxicity in animal models is not the same as demonstrated safety in humans. Additional concerns specific to BPC-157's practical context include:

• Products sold through unregulated channels have no verified purity, potency, or sterility — contaminants in injectable research chemicals represent a direct safety risk independent of the compound's own pharmacological profile.
• The plasma half-life under 30 minutes creates uncertainty about what dosing frequency and route of administration would be required to achieve any sustained biological effect, and what exposure levels would result from real-world use patterns.
• No human pharmacokinetic data are published; absorption, distribution, metabolism, and excretion in humans are unknown.
• Individuals with active malignancy, autoimmune conditions, or who are taking anticoagulant medications should be particularly cautious, given BPC-157's proposed pro-angiogenic and pro-healing mechanisms, which could theoretically interact with these conditions. This is speculative extrapolation; no human data exist to quantify the risk.
• Pregnant or breastfeeding individuals should not consider investigational compounds without established human safety data.

Biomarkers Relevant to Peptide Therapy Evaluation

If you are evaluating your biological baseline before exploring any investigational compound, several standard bloodwork markers are directly relevant to the mechanisms BPC-157 research centers on. Understanding where these markers stand before any intervention makes any subsequent changes interpretable. Superpower does not facilitate access to BPC-157, but these markers are part of standard comprehensive testing and are worth establishing regardless of what you are considering.

• High-sensitivity C-reactive protein (hs-CRP): The primary clinical marker of systemic inflammation. BPC-157 research centers on anti-inflammatory and tissue-protective mechanisms, making hs-CRP the most directly relevant bloodwork reference point. Elevated hs-CRP is associated with active inflammation from multiple sources; establishing a baseline value contextualizes whether any downstream change is meaningful.
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): Liver enzyme markers that reflect hepatocellular integrity. When evaluating any investigational compound, especially those obtained outside regulated channels, ALT and AST provide a baseline reference for liver function. Elevated values before starting any new compound complicate later interpretation.
• Estimated glomerular filtration rate (eGFR): A measure of kidney filtration function. Kidney function baseline is a standard safety reference point before using any investigational substance, particularly injectable ones with unknown pharmacokinetics.
• Complete metabolic panel (CMP): Provides comprehensive organ function data including liver enzymes, kidney function, glucose, and electrolytes. Establishing a pre-intervention CMP creates a reference standard against which any future changes can be evaluated in context.
• Complete blood count (CBC): BPC-157's proposed pro-angiogenic mechanism involves vascular biology. A baseline CBC documents red blood cell indices, white cell differential, and platelet count — relevant context for any compound with proposed vascular activity.

Understanding Your Baseline Before Considering Any Investigational Compound

BPC-157 illustrates a pattern common to many investigational compounds: a large volume of animal research, a compelling set of proposed mechanisms, and a persistent gap between what laboratory models show and what any human being can confidently conclude about their own body. That gap matters most when someone is deciding whether to use something. The markers most relevant to BPC-157's proposed biology — inflammatory load, liver and kidney function, vascular baseline — are exactly the markers that standard comprehensive bloodwork measures. Establishing those values first is not just prudent; it is the only way to make any future observation interpretable.

That principle — measure first, then decide — is central to Superpower's approach to preventive health: the belief that objective biomarker data should precede any clinical decision, not follow it. If you are concerned about joint recovery, gut health, or systemic inflammation, the clearest first step is understanding where your relevant markers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not FDA-approved for any indication. As of September 2023, BPC-157 is classified as a Category 2 bulk drug substance on the FDA's 503A bulk substances list, meaning it is prohibited for use in compounding by licensed pharmacies in the United States. Superpower Health does not prescribe, sell, compound, or facilitate access to BPC-157. This educational content is provided for informational purposes only and does not constitute medical advice, a recommendation to use this compound, or guidance on obtaining it through any channel.

No completed controlled human efficacy trials for BPC-157 have been published as of April 2026. All mechanistic claims in this article reflect preclinical (animal) research. Animal model findings frequently do not translate to human outcomes. The safety and efficacy of BPC-157 for any use in humans have not been established through adequate and well-controlled clinical trials.

Products marketed as BPC-157 through unregulated channels have no verified purity, potency, or sterility. Use of such products carries risks related to contamination, unknown dosing, and unknown pharmacokinetics that are independent of the compound's pharmacological profile.

As of the 2022 WADA Prohibited List, BPC-157 is prohibited at all times under S0 (Unapproved Substances) and is not eligible for a Therapeutic Use Exemption.

Do not use BPC-157 if you have active malignancy, are pregnant or breastfeeding, or are taking anticoagulant medications, without first consulting a qualified healthcare provider. These are precautionary considerations based on the compound's proposed mechanisms; no human safety data exists to quantify these risks.

Full compound reference data: PubChem CID 108101. FDA 503A bulk substances status: FDA bulk drug substances list.

Additional Questions

What does WADA's ban on BPC-157 mean for athletes?

As of the 2022 WADA Prohibited List, BPC-157 is prohibited at all times under Section S0 (Unapproved Substances). An athlete who tests positive for BPC-157 faces the same anti-doping consequences as a positive test for any other banned substance. BPC-157 is not eligible for a Therapeutic Use Exemption because no regulatory authority has approved it for any therapeutic indication. Athletes subject to anti-doping testing should treat any product containing or potentially contaminated with BPC-157 as a prohibited substance.

Is BPC-157 the same as a compounded medication?

No. A compounded medication is a pharmaceutical preparation made by a licensed 503A or 503B pharmacy from ingredients on the FDA's approved bulk substances list. BPC-157 is not on the approved 503A bulk substances list — it is on the Category 2 list, which prohibits its use in compounding. Products sold as "compounded BPC-157" are not legally compounded medications. They are unregulated products produced outside the pharmaceutical regulatory system.